How do you treat metastatic RCC with fumarate hydratase mutation (Hereditary Leiomyomatosis and RCC [HLRCC])?
There was an abstract in European J of Cancer (Srinivasan R, 2014:50: S6, P8) showing a good response rate with Bevacizumab and Erlotinib. Would you use this regimen with new generation of potent TKIs and check point inhibitors?